NRx Pharmaceuticals (NRXP) Moody Capital Disruptive Growth & Life Science Conference summary

Key announcements and strategic updates

• Recently acquired a clinical-stage biotech focused on diseases linked to ancient viral DNA, with the acquisition finalized just weeks ago.

• Announced approval of a Europe-wide patent for ALS diagnostics using proprietary technology.

• Initiated manufacturing of a monoclonal antibody drug for ALS, with human-grade product expected by July 2027 and clinical trials planned in partnership with NIH.

• Qualified for the first round of Congressionally Directed Medical Research Programs, with $80 million earmarked in the 2027 defense bill for ALS clinical trials.

• Launching a $5 million crowdfunding raise to support early-stage development.

Scientific and clinical insights

• Human endogenous retroviruses (HERVs) make up 8% of the human genome and are implicated in diseases like ALS, MS, schizophrenia, and glioblastoma.

• HERV-K envelope protein is found in the CSF of most ALS patients and is neurotoxic; monoclonal antibodies targeting this protein have shown efficacy in preclinical models.

• Prior clinical trials with a related antibody in MS showed decreased neurodegeneration and no safety issues in over 400 patients.

• FDA is open to accelerated, biomarker-based approvals for ALS drugs, lowering the clinical development risk.

• Military veterans and contact sport athletes have a 2–3x higher risk of ALS, supporting military funding interest.

Partnerships, leadership, and intellectual property

• Collaborations include NIH, Congressionally Directed Medical Research Program, Target ALS, Paris Brain Institute, and University of Basel.

• Leadership team includes experts with extensive drug development and regulatory experience, including former FDA officials and leading scientists.

• Holds seven patent families with 25 patents granted globally, expecting to reach 100 by clinical launch.

• U.S. government is a co-inventor and receives a 3% royalty on future drug approvals.

• Clean cap table due to acquisition through bankruptcy, with over €150 million previously invested in R&D.